Yes, predictive models and tools are being developed to assess cancer aggressiveness. These models use data from genetic tests, imaging, and patient history to predict outcomes and inform treatment decisions. Tools like Oncotype DX for breast cancer and Prolaris for prostate cancer are examples of such predictive assays.
